This study aims to evaluate the effectiveness of imiquimod treatment of external anogenital
warts and analyse its possible relationship with patient treatment satisfaction and …

Objective: To investigate the efficacy and safety of imiquimod 5% cream in the treatment of
anogenital warts in a female population. Methods: In two open-label studies, female patients …

Our objective was to determine the efficacy and safety of imiquimod 5% cream in the
treatment of external genital/perianal warts in an open-label Phase IIIB trial. Patients applied …

The experience and satisfaction of healthcare providers and patients were assessed for
various treatment options for anogenital warts. Patients were asked about their immediate …

Our objective was to determine patient attitudes to having genital warts, and their
perceptions of their treatment with imiquimod and other therapies. As an adjunct to a clinical …

Aim The clinical effects of home-therapy with 5% imiquimod cream in the treatment of
cutaneous anogenital warts are evaluated. Methods From March 2000 to January 2002, 57 …

Objective: The purpose of this double-blind, placebo-controlled study was to evaluate the
safety, clinical efficacy and tole-rability of imiquimod (2%) in cream to cure external genital …

Objective. To evaluate if new imiquimod formulations using a shorter treatment duration are
safe and efficacious to treat anogenital warts. Methods. In two studies 534 women≥ 12 …

Imiquimod 5% cream (Aldara, Graceway Pharmaceuticals) is an immune response modifier
used for the topical treatment of anogenital warts in non-HIV-infected patients. Several …

BACKGROUND: HIV-positive patients have unpredictable local immune responses even
with severe systemic immunosuppression and data reported to date is insufficient to predict …